
Patients with small-cell lung cancer (SCLC) do not have improved overall survival (OS) with supraprophylactic doses of low-molecular weight heparin (LWMH) added to standard therapy, according to a study published in the Annals of Oncology.
Coagulative disorders, such as venous thromboembolism (VTE), are frequent complications among patients with cancer and are significant contributors to poor outcomes. Previous study showed that anti-coagulants may not only have anti-tumorigenic activity, but also the potential to provide significant survival benefit for patients with SCLC.
For the phase 3 RASTEN trial, researchers randomly assigned 377 patients with newly diagnosed SCLC to receive standard treatment (chemoradiotherapy) with or without daily supraprophylactic enoxaparin 1 mg/kg for 21 days. Follow-ups were performed every 2 months at the start of each chemotherapy cycle.
Source: Cancer Therapy Advisor







